Incresync is developed by University Medical Centre Ljubljana.

What development phase is Incresync in?

Incresync is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Incresync

University Medical Centre Ljubljana · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Incresync
Sponsor	University Medical Centre Ljubljana
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants (PHASE1)
Comparison of Alogliptin Versus Alogliptin and Pioglitazone on Insulin Resistance of Metformin Treated Women With PCOS (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Incresync CI brief — competitive landscape report
Incresync updates RSS · CI watch RSS
University Medical Centre Ljubljana portfolio CI